Tiande Chemical Holdings Limited (Incorporated in the Cayman Islands with limited liability) (Stock code: 609) N O T I F I C AT I O N L E T T E R Dear Non-registered Holders(Note 1) , Tiande Chemical Holdings Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") Please note that both the English and Chinese versions of all future Corporate Communications will be available electronicall y on the website of the Company at www.tdchem.com and the HKEXnew ...

Tiande Chemical Holdings Limited (Incorporated in the Cayman Islands with limited liability) To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by sca nning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road Ea st, Wanchai, Hong Kong. (S ...

INTERIM REPORT 中期報告 2025 目錄 CONTENTS | 2 | 公司資料 | | --- | --- | | | Corporate Information | | 4 | 簡明綜合收益表 | | | Condensed Consolidated Income Statement | | 5 | 簡明綜合全面收益表 | | | Condensed Consolidated Statement of Comprehensive Income | | 6 | 簡明綜合財務狀況表 | | | Condensed Consolidated Statement of Financial Position | | 7 | 簡明綜合現金流量表 | | | Condensed Consolidated Statement of Cash Flows | | 8 | 簡明綜合權益變動表 | | | Condensed Consolidated Statement of Changes in Equity | | 10 | 簡明綜合財務報表附註 | | | Notes to the Condensed Co ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 天德化工控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00609 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | ...

格隆汇8月25日丨天德化工(00609.HK)公告，截至2025年6月30日止6个月，营业额约人民币9.32亿元， 较去年同期下跌5.6%。公司拥有人应占溢利下跌至约人民币3520万元(截至2024年6月30日止6个月：人 民币4240万元)。每股基本盈利约人民币0.040元(截至2024年6月30日止6个月：人民币0.049元)。董事会 不建议就截至2025年6月30日止6个月派发任何中期股息(截至2024年6月30日止6个月：港币0.02元)。 由于国内经济持续低迷，集团于回顾期内的产品整体售价持续显著下跌。尽管营商环境充满挑战，海外 市场营业额仍录得温和增长，但截至2025年6月30日止6个月，集团总营业额仍下跌。 ...

Group 1 - The company Tian De Chemical (00609) reported a revenue of 932 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 5.62% [1] - The profit attributable to shareholders was 35.154 million RMB, which is a year-on-year decline of 17.01% [1] - The basic earnings per share were 0.04 RMB [1]

Group 1 - The company Tian De Chemical (00609) reported a revenue of 932 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 5.62% [1] - The profit attributable to shareholders was 35.154 million RMB, which is a year-on-year decrease of 17.01% [1] - The basic earnings per share were 0.04 RMB [1]

Performance Highlights [Financial Performance Overview](index=1&type=section&id=Financial%20Performance%20Overview) The company experienced declines in turnover, gross profit, profit attributable to owners, and basic EPS for H1 2025, with no interim dividend recommended H1 2025 Performance Summary | Metric | H1 2025 (RMB) | H1 2024 (RMB) | Y-o-Y Change | | :--- | :--- | :--- | :--- | | Turnover | 932,300,000 | 987,765,000 | Decreased 5.6% | | Gross Profit | 116,700,000 | 144,084,000 | Decreased 19.0% | | Gross Profit Margin | 12.5% | 14.6% | Decreased 2.1 percentage points | | Profit attributable to owners of the Company for the period | 35,200,000 | 42,400,000 | Decreased 16.98% | | Basic earnings per share | 0.040 | 0.049 | Decreased 18.37% | | Interim Dividend | Not recommended for distribution | HKD 0.02 | Not distributed | Condensed Consolidated Financial Statements [Condensed Consolidated Statement of Profit or Loss](index=2&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) For H1 2025, group turnover decreased by 5.6% to RMB 932,301 thousand, gross profit fell by 19.0% to RMB 116,676 thousand, and profit for the period was RMB 19,231 thousand Condensed Consolidated Statement of Profit or Loss (For the six months ended June 30) | Metric | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Turnover | 932,301 | 987,765 | | Cost of sales | (815,625) | (843,681) | | Gross Profit | 116,676 | 144,084 | | Other income and gains | 18,100 | 18,166 | | Selling expenses | (40,747) | (36,327) | | Administrative and other operating expenses | (52,197) | (83,289) | | Finance costs | (6,395) | (638) | | Profit before income tax | 35,437 | 41,996 | | Income tax expense | (16,206) | (8,146) | | Profit for the period | 19,231 | 33,850 | | Profit attributable to owners of the Company for the period | 35,154 | 42,357 | | Profit/(Loss) attributable to non-controlling interests for the period | (15,923) | (8,507) | | Basic earnings per share | RMB 0.040 | RMB 0.049 | | Diluted earnings per share | RMB 0.040 | RMB 0.049 | [Condensed Consolidated Statement of Comprehensive Income](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) Total comprehensive income for H1 2025 significantly decreased to RMB 13,056 thousand, primarily due to a shift from gain to loss in currency translation differences Condensed Consolidated Statement of Comprehensive Income (For the six months ended June 30) | Metric | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Profit for the period | 19,231 | 33,850 | | Other comprehensive income - Currency translation differences | (6,175) | 737 | | Total comprehensive income for the period | 13,056 | 34,587 | | Total comprehensive income attributable to owners of the Company | 28,803 | 43,242 | | Total comprehensive income attributable to non-controlling interests | (15,747) | (8,655) | [Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, total assets less current liabilities slightly decreased, with increases in trade and bills receivables and cash balances, and a significant reduction in time deposits Condensed Consolidated Statement of Financial Position (As of June 30) | Metric | June 30, 2025 (RMB '000) | December 31, 2024 (RMB '000) | | :--- | :--- | :--- | | Non-current assets | 1,662,114 | 1,659,245 | | Current assets | 1,520,861 | 1,425,188 | | Current liabilities | 653,606 | 524,507 | | Net current assets | 867,255 | 900,681 | | Total assets less current liabilities | 2,529,369 | 2,559,926 | | Non-current liabilities | 24,778 | 45,002 | | Net assets | 2,504,591 | 2,514,924 | | Equity attributable to owners of the Company | 2,425,517 | 2,420,103 | | Non-controlling interests | 79,074 | 94,821 | | Total equity | 2,504,591 | 2,514,924 | - Within current assets, **trade and bills receivables increased from RMB 377,774 thousand to RMB 461,932 thousand**, and **bank and cash balances increased from RMB 358,214 thousand to RMB 633,913 thousand**, while **time deposits decreased from RMB 493,340 thousand to RMB 215,006 thousand**[5](index=5&type=chunk) - Bank borrowings within current liabilities significantly **increased from RMB 220,134 thousand to RMB 354,191 thousand**[5](index=5&type=chunk) Notes to the Financial Statements [General Information](index=5&type=section&id=1.%20General%20Information) TianDe Chemical Holdings Limited is an exempted company incorporated in the Cayman Islands, primarily engaged in investment holding and the R&D, manufacturing, and sale of fine chemical products - The Company is an exempted company incorporated in the Cayman Islands, with shares listed on the Hong Kong Stock Exchange[6](index=6&type=chunk) - The Company's principal business is investment holding, while the Group's principal activities are the research, development, manufacturing, and sale of fine chemical products[7](index=7&type=chunk) [Basis of Preparation and Presentation](index=5&type=section&id=2.%20Basis%20of%20Preparation%20and%20Presentation) The unaudited condensed consolidated financial statements are prepared in accordance with HKAS 34 and Appendix D2 of the Listing Rules, presented in RMB, and reviewed by BDO Limited - The financial statements are prepared in accordance with Hong Kong Accounting Standard 34 and Appendix D2 of the Listing Rules[8](index=8&type=chunk) - The Company's functional currency is HKD, but financial information is presented in RMB due to its principal operations being in China[8](index=8&type=chunk) - The financial information is unaudited but has been reviewed by BDO Limited[8](index=8&type=chunk) [Significant Accounting Policies](index=5&type=section&id=3.%20Significant%20Accounting%20Policies) Amendments to HKAS 21 and HKFRS 1, concerning non-exchangeable currencies and exchange rate estimation, were first applied this interim period with no significant impact, while HKFRS 18 is expected to significantly affect financial statement presentation - The first-time application of amendments to Hong Kong Accounting Standard 21 and Hong Kong Financial Reporting Standard 1, concerning the assessment of non-exchangeable currencies, had **no impact on the Group's condensed consolidated interim financial statements**[9](index=9&type=chunk)[10](index=10&type=chunk) - Hong Kong Financial Reporting Standard 18 will replace Hong Kong Accounting Standard 1, and is expected to have a **significant impact on the classification of profit or loss, subtotals, aggregation/disaggregation of information, and disclosure of management performance measures**[11](index=11&type=chunk) [Turnover and Segment Information](index=7&type=section&id=4.%20Turnover%20and%20Segment%20Information) The Group identifies R&D, manufacturing, and sale of fine chemical products as a single operating segment, with total turnover of RMB 932,301 thousand for H1 2025, showing decreased domestic sales but increased sales in UAE, USA, and Brazil - The Group identifies the research, development, manufacturing, and sale of fine chemical products as a **single operating segment**[12](index=12&type=chunk) Classified Turnover from External Customers (By Geographical Region) | Region | 2025 (RMB '000) | 2024 (RMB '000) | Y-o-Y Change | | :--- | :--- | :--- | :--- | | China (Domestic) | 643,615 | 708,475 | -9.29% | | India | 103,938 | 124,289 | -16.40% | | United Arab Emirates | 41,891 | 24,533 | +70.76% | | United States | 29,300 | 16,375 | +78.93% | | Brazil | 21,459 | 6,112 | +251.10% | | Others | 92,098 | 107,981 | -14.71% | | **Total** | **932,301** | **987,765** | **-5.62%** | - For the period ended June 30, 2025, **no single customer accounted for 10% or more of the Group's revenue**[14](index=14&type=chunk) [Finance Costs](index=7&type=section&id=5.%20Finance%20Costs) Finance costs for H1 2025 significantly increased to RMB 6,395 thousand from RMB 638 thousand in the prior period, driven by interest on bank borrowings, asset-backed financing, and supplier financing arrangements Finance Costs Details (For the six months ended June 30) | Item | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Interest on bank borrowings repayable within one year and containing a repayment on demand clause | 2,701 | 638 | | Interest on asset-backed financing | 391 | - | | Interest on supplier financing arrangements | 3,202 | - | | Interest on advances from related parties | 101 | - | | **Total** | **6,395** | **638** | [Profit Before Income Tax](index=8&type=section&id=6.%20Profit%20Before%20Income%20Tax) Profit before income tax for H1 2025 was RMB 35,437 thousand, with decreased total employee costs but increased inventory costs and depreciation of property, plant, and equipment, alongside a significant reduction in research costs Profit Before Income Tax Deducted/(Credited) Items (For the six months ended June 30) | Item | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Total employee costs | 83,686 | 97,910 | | Depreciation of right-of-use assets | 1,287 | 1,287 | | Amortisation of intangible assets | 902 | 902 | | Cost of inventories recognised as expense | 815,625 | 843,681 | | Depreciation of property, plant and equipment | 90,487 | 83,700 | | (Gain)/Loss on disposal of property, plant and equipment, net | (1,018) | 43 | | Provision for impairment loss on trade receivables | 1,484 | 110 | | Loss on write-off of property, plant and equipment | 2,353 | 8 | | Research costs | 22,669 | 54,426 | - **Research costs significantly decreased from RMB 54,426 thousand in H1 2024 to RMB 22,669 thousand in H1 2025**[16](index=16&type=chunk) - **Depreciation of property, plant and equipment increased from RMB 83,700 thousand in H1 2024 to RMB 90,487 thousand in H1 2025**[16](index=16&type=chunk) [Income Tax Expense](index=9&type=section&id=7.%20Income%20Tax%20Expense) Income tax expense for H1 2025 significantly increased to RMB 16,206 thousand from RMB 8,146 thousand in the prior period, primarily due to a substantial rise in withholding tax paid on China dividends Income Tax Expense Details (For the six months ended June 30) | Item | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Current tax—China corporate income tax - Tax for the period | 11,319 | 9,167 | | Current tax—China corporate income tax - Over-provision in prior years | (641) | (1,172) | | Current tax—China corporate income tax - Withholding tax paid on China dividends | 25,706 | 970 | | Deferred tax - Credit for the period | (20,178) | (819) | | **Total Income Tax Expense** | **16,206** | **8,146** | - **Withholding tax paid on China dividends significantly increased from RMB 970 thousand in H1 2024 to RMB 25,706 thousand in H1 2025**[17](index=17&type=chunk) - China subsidiaries are subject to corporate income tax at a rate of **25%**, with China withholding tax rates of **5% or 10%**[18](index=18&type=chunk) [Dividends](index=9&type=section&id=8.%20Dividends) Shareholders approved a final dividend of HKD 0.03 per share for 2024, but the Board does not recommend any interim dividend for H1 2025, compared to HKD 0.02 per share in the prior period - The 2024 final dividend of **HKD 0.03 per share** (2023: HKD 0.10) was approved at the AGM on June 6, 2025, totaling **RMB 24,218,000**[19](index=19&type=chunk) - The Board does not recommend any interim dividend for the six months ended June 30, 2025 (H1 2024: HKD 0.02 per share)[19](index=19&type=chunk) [Earnings Per Share](index=10&type=section&id=9.%20Earnings%20Per%20Share) Basic and diluted earnings per share attributable to owners of the Company for H1 2025 both decreased to RMB 0.040, down from RMB 0.049 in the prior period Earnings Per Share Calculation Data (For the six months ended June 30) | Metric | 2025 (RMB '000/thousand shares) | 2024 (RMB '000/thousand shares) | | :--- | :--- | :--- | | Profit attributable to owners of the Company for the period | 35,154 | 42,357 | | Weighted average number of ordinary shares for basic EPS | 877,462 | 869,418 | | Dilutive effect of potential ordinary shares - Share options | 44 | 4,188 | | Weighted average number of ordinary shares for diluted EPS | 877,506 | 873,606 | | **Basic earnings per share** | **RMB 0.040** | **RMB 0.049** | | **Diluted earnings per share** | **RMB 0.040** | **RMB 0.049** | [Trade and Bills Receivables](index=10&type=section&id=10.%20Trade%20and%20Bills%20Receivables) As of June 30, 2025, total trade and bills receivables increased to RMB 461,932 thousand from RMB 377,774 thousand at December 31, 2024, with a notable increase in receivables over 365 days - The Group generally grants credit terms of **one to six months** to its trade customers[21](index=21&type=chunk) Ageing Analysis of Trade and Bills Receivables (By invoice date) | Ageing | June 30, 2025 (RMB '000) | December 31, 2024 (RMB '000) | | :--- | :--- | :--- | | 0 to 90 days | 321,193 | 275,588 | | 91 to 180 days | 49,260 | 87,238 | | 181 to 365 days | 78,260 | 14,753 | | Over 365 days | 13,219 | 195 | | **Total** | **461,932** | **377,774** | [Trade Payables](index=11&type=section&id=11.%20Trade%20Payables) As of June 30, 2025, total trade payables slightly increased to RMB 40,755 thousand from RMB 37,901 thousand at December 31, 2024, with credit terms from suppliers ranging from 30 to 270 days - The Group is granted credit terms by its suppliers ranging from **30 to 270 days**[22](index=22&type=chunk) Ageing Analysis of Trade Payables (By invoice date) | Ageing | June 30, 2025 (RMB '000) | December 31, 2024 (RMB '000) | | :--- | :--- | :--- | | 0 to 90 days | 35,600 | 32,497 | | 91 to 180 days | 851 | 1,798 | | 181 to 365 days | 1,666 | 1,533 | | Over 365 days | 2,638 | 2,073 | | **Total** | **40,755** | **37,901** | Management Discussion and Analysis [Business Review](index=11&type=section&id=Business%20Review) Domestic manufacturing faces downward pressure from macroeconomic headwinds, geopolitical tensions, and US tariffs, but the Group's overseas market expansion and capacity increase for potential products partially offset negative impacts, leading to a slight decline in total turnover - Persistent adverse macroeconomic factors, international geopolitical tensions, and US tariff policies have severely impacted domestic manufacturing, leading to **increased downward pressure on the overall domestic economy and declining product selling prices**[23](index=23&type=chunk) - The Group strategically allocated marketing resources to developing overseas markets, achieving **moderate year-on-year growth in overseas sales** through an expanded international marketing network[23](index=23&type=chunk) - Expanding production capacity for products with market potential successfully opened new application areas in downstream industries and broadened product applications in international markets, helping to **mitigate the adverse effects of declining product selling prices**[23](index=23&type=chunk) - Domestic deflation led to a decrease in average raw material costs, and the Group improved efficiency through automated production and a circular economy system, but these efforts could not fully offset the negative impact of declining product selling prices, resulting in **reduced gross profit and gross profit margin**[24](index=24&type=chunk) [Outlook](index=12&type=section&id=Outlook) Facing US-China trade tensions, domestic economic slowdown, and deflation, the Group is actively expanding its business scope, diversifying risks, enhancing operational flexibility, optimizing product portfolio, and seeking new revenue streams, while strengthening cash flow management and maintaining confidence in long-term prospects - Ongoing US-China trade tensions and US tariff policies pose significant pressure on the domestic economy, with a **continued slowdown and deepening deflation expected to bring severe challenges to domestic manufacturing**[25](index=25&type=chunk) - The Group is actively expanding its business scope and diversifying its business risks, enhancing operational flexibility, continuously optimizing its product portfolio, and actively seeking new revenue sources[25](index=25&type=chunk) - Strengthening cash flow management and improving operational efficiency remain key priorities for the Group, and the Board remains **confident in the Group's long-term prospects**[25](index=25&type=chunk) [Financial Review](index=12&type=section&id=Financial%20Review) Turnover decreased by 5.6% to RMB 932.3 million due to domestic economic downturn and falling product prices; gross profit fell 19.0% to RMB 116.7 million, with margin shrinking to 12.5%; selling expenses rose, administrative expenses decreased, and finance costs significantly increased [Turnover and Gross Profit](index=12&type=section&id=Turnover%20and%20Gross%20Profit) Total turnover decreased by 5.6% to RMB 932.3 million due to domestic economic downturn and falling product prices; gross profit fell 19.0% to RMB 116.7 million, with margin shrinking to 12.5%, despite lower raw material costs and improved efficiency - Total turnover **decreased by 5.6% to approximately RMB 932.3 million** (H1 2024: RMB 987.8 million), primarily due to a significant decline in overall product selling prices caused by the prolonged domestic economic downturn[26](index=26&type=chunk) - Gross profit **decreased by 19.0% to approximately RMB 116.7 million** (H1 2024: RMB 144.1 million), and gross profit margin **contracted by 2.1 percentage points to 12.5%** (H1 2024: 14.6%), mainly because the decline in product selling prices was not fully offset by lower raw material costs and improved operational efficiency[27](index=27&type=chunk) [Operating Expenses](index=13&type=section&id=Operating%20Expenses) Selling expenses increased by 12.1% to RMB 40.7 million due to higher transportation costs from increased domestic sales of hazardous products, while administrative and other operating expenses significantly decreased by 37.3% to RMB 52.2 million, mainly due to lower research and development expenses - Selling expenses **increased by approximately RMB 4.4 million to approximately RMB 40.7 million**, primarily due to higher transportation costs resulting from increased domestic sales of hazardous products[28](index=28&type=chunk) - Administrative and other operating expenses **decreased by approximately RMB 31.1 million or 37.3% to approximately RMB 52.2 million**, mainly due to a reduction in research and development expenses[28](index=28&type=chunk) [Finance Costs](index=13&type=section&id=Finance%20Costs) Finance costs significantly increased by approximately RMB 5.8 million to RMB 6.4 million, primarily due to a strategic increase in bank borrowings, asset-backed financing, supplier financing arrangements, and advances from related parties to optimize short-term liquidity management - Finance costs were approximately **RMB 6.4 million**, an **increase of approximately RMB 5.8 million** compared to the same period last year, primarily from interest on bank borrowings, asset-backed financing, supplier financing arrangements, and advances from related parties[29](index=29&type=chunk) - The Group strategically increased its use of bank borrowings and other methods to **optimize short-term liquidity management**[29](index=29&type=chunk) [Profit for the Period](index=13&type=section&id=Profit%20for%20the%20Period) Profit attributable to owners of the Company for the period under review was approximately RMB 35.2 million, a decrease from RMB 42.4 million in the prior period - Profit attributable to owners of the Company for the period under review was approximately **RMB 35.2 million** (H1 2024: RMB 42.4 million)[30](index=30&type=chunk) [Trade and Bills Receivables](index=13&type=section&id=Trade%20and%20Bills%20Receivables) As of June 30, 2025, trade receivables (net of impairment allowance) increased by 19.1% to RMB 323.8 million, with approximately 28.3% aged over 180 days; bills receivables rose by 30.3% to RMB 138.1 million, all being bank acceptance bills with low default risk - Trade receivables (net of allowance for impairment losses) **increased by 19.1% to approximately RMB 323.8 million** (December 31, 2024: RMB 271.8 million)[31](index=31&type=chunk) - Approximately **28.3% of trade receivables were aged over 180 days**, but the Directors believe no additional bad debt provision is required[31](index=31&type=chunk) - Bills receivables **increased by 30.3% to approximately RMB 138.1 million** (December 31, 2024: RMB 106.0 million), all of which are bank acceptance bills with low default risk[32](index=32&type=chunk) [Short-term Bank Borrowings](index=14&type=section&id=Short-term%20Bank%20Borrowings) As of June 30, 2025, total bank borrowings increased to RMB 354.2 million, primarily utilized to fund the Group's general working capital - Total bank borrowings outstanding **increased to approximately RMB 354.2 million** (December 31, 2024: RMB 220.1 million)[33](index=33&type=chunk) - The bank borrowings were primarily raised to fund the Group's **general working capital** during the period under review[33](index=33&type=chunk) [Liquidity and Financial Resources](index=14&type=section&id=Liquidity%20and%20Financial%20Resources) Net cash inflow from operating activities for H1 2025 significantly decreased to RMB 50.3 million, and the Group's net cash balance declined to RMB 490.4 million, yet it maintains a sound financial position with cash and cash equivalents exceeding total outstanding borrowings - Net cash inflow from operating activities was approximately **RMB 50.3 million** (H1 2024: RMB 151.8 million), representing a **significant decrease**[34](index=34&type=chunk) - New bank borrowings amounted to approximately **RMB 118.6 million**, and advances from related parties were **RMB 12.0 million**[34](index=34&type=chunk) - Net cash balance was approximately **RMB 490.4 million** (December 31, 2024: RMB 626.9 million), showing a **decrease**[35](index=35&type=chunk) - The Group maintained a **sound financial position** during the period under review, with cash and cash equivalents exceeding total outstanding borrowings, and the debt-to-equity ratio is not applicable[35](index=35&type=chunk) [Pledge of Assets](index=15&type=section&id=Pledge%20of%20Assets) As of June 30, 2025, the Group pledged RMB 1.3 million in bank deposits as security and certain buildings (RMB 50.4 million) and right-of-use assets (RMB 76.6 million) as collateral for bank borrowings - Bank deposits of approximately **RMB 0.3 million were pledged as security for factory water supply**, and **RMB 1.0 million was pledged as security for foreign exchange forward contracts**[38](index=38&type=chunk) - Certain buildings (approximately **RMB 50.4 million**) and right-of-use assets (approximately **RMB 76.6 million**) were pledged as collateral for bank borrowings[38](index=38&type=chunk) [Contingent Liabilities](index=15&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no significant contingent liabilities - As of June 30, 2025, the Group had **no significant contingent liabilities**[39](index=39&type=chunk) [Foreign Exchange Fluctuation Risk](index=15&type=section&id=Foreign%20Exchange%20Fluctuation%20Risk) The Group's primary operations are in China, with assets, liabilities, turnover, and transactions mainly denominated in RMB, USD, and HKD; the main foreign exchange risk stems from RMB fluctuations, which caused no significant issues during the period, and cost-effective hedging methods will be considered in the future - The Group's assets, liabilities, turnover, and transactions are primarily denominated in **RMB, USD, and HKD**[40](index=40&type=chunk) - The most significant foreign exchange fluctuation risk arises from **RMB exchange rate changes**, but no major difficulties or impacts were encountered during the period under review[40](index=40&type=chunk) - The Group will consider adopting **cost-effective hedging methods** for foreign currency transactions when appropriate in the future[40](index=40&type=chunk) [Dividends](index=15&type=section&id=Dividends) The Board does not recommend any interim dividend for the six months ended June 30, 2025 - The Board does not recommend any interim dividend for the six months ended June 30, 2025 (H1 2024: HKD 0.02 per share)[41](index=41&type=chunk) Other Information [Human Resources](index=15&type=section&id=Human%20Resources) As of June 30, 2025, the Group had 1,213 full-time employees, a decrease from 1,358 at year-end 2024, with established remuneration, bonus, and diverse training and development programs to enhance employee skills and industry knowledge - As of June 30, 2025, the Group had **1,213 full-time employees** (December 31, 2024: 1,358 full-time employees)[42](index=42&type=chunk) - The Group has established human resources policies and systems, including **remuneration, bonuses, diverse training, and personal development programs**[42](index=42&type=chunk) - The Group adopted a share option scheme to reward contributors, but **no share options were granted** during the period under review[43](index=43&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=16&type=section&id=Purchase,%20Sale%20or%20Redemption%20of%20the%20Company's%20Listed%20Securities) For the six months ended June 30, 2025, neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's listed shares - For the six months ended June 30, 2025, **neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed shares**[44](index=44&type=chunk) [Corporate Governance Practices](index=16&type=section&id=Corporate%20Governance%20Practices) To the best of the Directors' knowledge, the Company has complied with the Corporate Governance Code set out in Appendix C1 Part 2 of the Listing Rules for the six months ended June 30, 2025 - The Company has **complied with the Corporate Governance Code** set out in Appendix C1 Part 2 of the Listing Rules for the six months ended June 30, 2025[45](index=45&type=chunk) [Standard Code for Securities Transactions](index=16&type=section&id=Standard%20Code%20for%20Securities%20Transactions) The Company has adopted a code of conduct no less exacting than the Standard Code in Appendix C3 of the Listing Rules, and all Directors and senior management have confirmed compliance - The Company has adopted a code of conduct **no less exacting than the Standard Code** set out in Appendix C3 of the Listing Rules, and each Director has confirmed compliance with the code[46](index=46&type=chunk) - Senior management is also required to comply with the provisions of the Standard Code and the Company's code of conduct regarding Directors' securities transactions[46](index=46&type=chunk) [Nomination Committee](index=16&type=section&id=Nomination%20Committee) The Nomination Committee is chaired by Executive Director Mr. Liu Yang and includes two independent non-executive Directors, with no meetings held during the period under review - The Nomination Committee is chaired by Executive Director Mr. Liu Yang, with members including Independent Non-executive Directors Mr. Leung Kam Wan and Mr. Liu Chenguang[47](index=47&type=chunk) - **No Nomination Committee meetings were held** during the period under review[47](index=47&type=chunk) [Remuneration Committee](index=17&type=section&id=Remuneration%20Committee) The Remuneration Committee is chaired by Independent Non-executive Director Mr. Liu Chenguang and has three other members, with no meetings held during the period under review - The Remuneration Committee is chaired by Independent Non-executive Director Mr. Liu Chenguang, with members including Independent Non-executive Directors Mr. Leung Kam Wan, Ms. Shan Honghong, and Executive Director Mr. Liu Yang[48](index=48&type=chunk) - **No Remuneration Committee meetings were held** during the period under review[48](index=48&type=chunk) [Audit Committee](index=17&type=section&id=Audit%20Committee) The Audit Committee, comprising three independent non-executive Directors and chaired by Mr. Leung Kam Wan, has reviewed accounting principles, internal controls, independent auditor's work, and the unaudited condensed financial information without objection - The Audit Committee comprises **three independent non-executive Directors**, with Mr. Leung Kam Wan as Chairman[49](index=49&type=chunk) - The Committee has reviewed the Company's adopted accounting principles and practices, compliance with Listing Rules, internal controls, statutory requirements, and financial reporting[49](index=49&type=chunk) - The Audit Committee has reviewed the unaudited condensed financial information and has **no objections to the accounting treatments adopted by the Company** during the period under review[49](index=49&type=chunk) [Events After the Reporting Period](index=17&type=section&id=Events%20After%20the%20Reporting%20Period) As of the announcement date, the Group had no other significant events after June 30, 2025 - As of the announcement date, the Group had **no other significant events after June 30, 2025**[50](index=50&type=chunk)

Group 1 - The company, Tiande Chemical (00609.HK), announced that it will hold a board meeting on August 25, 2025, to review and approve the unaudited interim results for the six-month period ending June 30, 2025, and to consider the declaration of an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 Tiande Chemical Holdings Limited 承董事會命 天德化工控股有限公司 劉偉珍 公司秘書 香港，二零二五年八月十一日 於本公告日期，執行董事為劉楊先生、王子江先生及陳孝華先生；獨立非執行董事為 梁錦雲先生、劉晨光先生及山紅紅女士。 - 1 - 天德化工控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號︰609） 董事會會議通告 天德化工控股有限公司（「本公司」）董事會（「董事會」）茲宣佈，謹定於二零二 五年八月二十五日（星期一）上午十一時正，於香港中環夏愨道 12 號美國銀行中心 2204A 室舉行董事會會議，以考慮並（若認為合適）批准（其中包括）本公司及其附 屬公司截至二零二五年六月三十日止六個月之未經審核的中期業績及其發佈，以及宣 派和支付中期股息（如有）。 ...